Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc. (ARWR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 2024 (First Quarter of Fiscal 2025)
Business Overview: Arrowhead develops medicines that treat intractable diseases by silencing genes using RNA interference (RNAi) technology. The company operates lab facilities in California and Wisconsin and maintains a pipeline of candidates in cardiometabolic, pulmonary, liver, muscle, and CNS therapeutic areas.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 (Ended Dec 31, 2024) | Q1 2024 (Ended Dec 31, 2023) |
|---|---|---|
| Revenue | $2,500 | $3,551 |
| Operating Loss | $(161,412) | $(136,545) |
| Net Loss (Attributable to Arrowhead) | $(173,085) | $(132,864) |
| Net Loss Per Share (Diluted) | $(1.39) | $(1.24) |
| Cash, Cash Equivalents, and Restricted Cash | $53,889 | $58,215 |
| Available-for-Sale Securities | $499,046 | $578,276 |
| Total Debt (Credit Facility) | $409,414 | $0 |
| Liability Related to Sale of Future Royalties | $346,776 | $341,361 |
| Net Cash Used in Operating Activities | $(146,272) | $(117,840) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $1.05 million (30%) to $2.5 million, primarily due to the completion of performance obligations under the Takeda license agreement, which generated $0.9 million in the prior year period.
- Increased Operating Expenses: Total operating expenses rose to $163.9 million from $140.1 million.
- R&D Expenses: Increased by $20.5 million (18%) to $137.0 million, driven by a $23.9 million increase in candidate costs as the pipeline advanced into later clinical phases.
- G&A Expenses: Increased by $3.3 million (14%) to $26.9 million, largely due to a $4.9 million increase in professional services related to business development and commercialization.
- Debt Financing: The company entered a new $500 million senior secured term loan facility in August 2024. As of December 31, 2024, the outstanding balance was approximately $409.4 million (including accrued interest), resulting in significant interest expense ($16.2 million) not present in the prior year.
- Liquidity Position: Total cash and investments decreased by approximately $128 million quarter-over-quarter due to operating burn and capital expenditures, partially offset by proceeds from pre-funded warrants.
Guidance, Outlook, and Material Events
- Sarepta Collaboration (Subsequent Event): On February 7, 2025, the company closed a global collaboration with Sarepta Therapeutics. Arrowhead received $325 million in equity investment and expects to receive $500 million in upfront payments in Q2 2025, plus $250 million in installments over five years. The deal includes potential milestones up to $10 billion.
- Regulatory Milestone: An NDA for plozasiran was accepted for filing by the FDA on January 17, 2025, with a PDUFA action date of November 18, 2025.
- Clinical Progress:
- GSK dosed the fifth patient in a Phase 2 trial for daplusiran/tomligisiran, triggering a $2.5 million milestone payment (received in Q2 2025).
- First subjects dosed in Phase 1/2a trials for ARO-INHBE (obesity) and ARO-ALK7.
- Interim data for ARO-CFB showed dose-dependent reductions in CFB protein by up to 90%.
- Liquidity Outlook: Management expects sufficient liquidity to fund operations for at least the next twelve months based on current cash, investments, and the anticipated Sarepta payments.
- Risks: The company remains subject to risks associated with clinical trial outcomes, regulatory approvals, and the ability to secure additional financing if needed. The new credit facility includes covenants requiring maintenance of specific liquidity levels.
Key Facts for Investor Verification
- Timing of Sarepta Payments: Verify the receipt of the $500 million upfront payment and the $325 million equity investment in Q2 2025 filings to confirm cash flow improvement.
- Debt Covenants: Monitor compliance with the new credit facility's liquidity covenant (maintaining at least $100 million in cash/investments if market cap exceeds $1.5 billion).
- Interest Expense Impact: Assess the ongoing impact of the $15% interest rate on the $400 million term loan on future net losses.
- Plozasiran Approval: Track the FDA review process for plozasiran with a decision expected by November 18, 2025.
- Capital Expenditures: Note the completion of the Verona, Wisconsin manufacturing facility, which has shifted costs from construction in progress to depreciation.